# Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis

> **NCT02782312** · PHASE4 · COMPLETED · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 120 (actual)

## Conditions studied

- Bronchiectasis

## Interventions

- **DRUG:** ICS+LABA
- **OTHER:** routine therapy

## Key facts

- **NCT ID:** NCT02782312
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2012-06
- **Final completion:** 2013-06
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2016-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02782312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02782312, "Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02782312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*